Key Highlights

  • Second-quarter Revenue was about $1.25 million, up 12% sequentially but down 55% year over year, with gross Margin expanding to 54% and a net loss of $4.0 million.
  • The year-over-year decline stemmed almost entirely from the cessation, in August 2025, of sales of a private-labeled pet-odor-control product.
  • Excluding that discontinued line, revenue rose about 26% in the first half, and its PFAS water-treatment system surpassed 10,000 hours of continuous operation at a New Jersey site.
  • Shares held flat as investors weighed the headline revenue decline against growth in the company's continuing businesses.

BioLargo (OTCQX:BLGO), a cleantech and life-sciences company with a portfolio spanning water treatment, environmental services, infection control and energy storage, held flat after a year-over-year revenue decline tied to a discontinued product line, even as its underlying businesses grow. For investors, the question is whether this diversified innovator can turn the headline story around as its core segments expand.

BioLargo develops and commercializes environmental and life-sciences technologies across several platforms, including a PFAS water-treatment system, industrial odor and air-quality control, environmental engineering services, wound-care products through a majority-owned subsidiary, and a liquid-sodium battery technology for grid-scale energy storage. This breadth gives it multiple potential growth avenues but also spreads its resources across early-stage ventures.

Latest Developments

In its second-quarter 2026 results, BioLargo reported revenue of about $1.25 million, up 12% sequentially from the first quarter but down 55% year over year, with gross margin expanding to 54% and a net loss of $4.0 million. The year-over-year decline stemmed almost entirely from the cessation, in August 2025, of sales of a private-labeled pet-odor-control product; excluding that discontinued line, revenue rose about 26% in the first half. Operationally, its PFAS water-treatment system surpassed 10,000 hours of continuous operation at a New Jersey site, its environmental engineering services and wound-care unit contributed revenue, and its liquid-sodium battery technology remained pre-revenue.

Financial and Business Position

BioLargo's headline revenue decline is misleading in isolation, since it reflects the loss of a single discontinued product line rather than broad weakness, and its continuing businesses actually grew. The company's diversified platform, particularly its PFAS water-treatment technology amid rising regulatory attention to those contaminants, and its grid-scale battery ambitions, offer genuine long-term potential. However, BioLargo remains unprofitable with a small revenue base, so converting its promising technologies into scaled, profitable operations is the central challenge.

Stock-Market Context

The stock carries a strong-buy rating, reflecting optimism about its cleantech platforms. The turnaround case rests on the PFAS water-treatment business scaling amid regulatory tailwinds, continued growth in its core segments, and eventual commercialization of its battery technology; the cautionary case is that a small, unprofitable company spread across multiple early-stage ventures faces execution and funding risks, and that the revenue decline, however explained, weighs on sentiment.

What Investors Should Watch

Investors may focus on growth in the continuing businesses excluding the discontinued product line, commercial traction for the PFAS water-treatment system amid tightening regulations, progress toward revenue at the liquid-sodium battery unit, gross-margin trends, and the company's cash position and funding. Evidence that its core technologies, especially PFAS treatment, are scaling toward meaningful revenue would be central to turning the story around.

BioLargo's headline revenue decline is genuinely misleading when viewed in isolation, since it stems almost entirely from the loss of a single private-labeled product line that was discontinued in mid-2025; excluding that, the company's continuing businesses actually grew. The company's value proposition lies in its diversified portfolio of environmental and life-sciences technologies, and the most compelling of these may be its PFAS water-treatment system, which addresses so-called forever chemicals that have become a major regulatory and public-health focus. For investors, the turnaround case rests on whether BioLargo can convert its promising technologies, especially PFAS treatment amid regulatory tailwinds, into scaled, profitable operations.